Article info
PDFOriginal research
Observational study on off-label use of tocilizumab in patients with severe COVID-19
- Correspondence to Dr Laetitia Albertini, Pharmacist, Montfermeil, France; albertini.laetitia{at}gmail.com
Citation
Observational study on off-label use of tocilizumab in patients with severe COVID-19
Publication history
- Received June 15, 2020
- Revised August 17, 2020
- Accepted August 18, 2020
- First published September 10, 2020.
Online issue publication
December 18, 2020
Article Versions
- Previous version (18 December 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage